Three countries claim they're winning healthcare AI. None can prove it helps patients yet.

Run time: 6:44

In today's episode:

1. US leads on approvals: 1,400-plus FDA-cleared AI devices
2. China leads on scale: DeepSeek live in 260-plus hospitals
3. UAE leads on data: ~1M genomes sequenced, open clinical LLM
4. Deep Knowledge index (May 2026): US 1, UK 2, China 3
5. The catch: almost none of it tied to patient outcomes

TL;DR:

• There's no single winner — the US leads on capital, approvals, and frontier models; China leads on national-scale deployment; the UAE leads on genomic depth and sovereign data. Different races, different scoreboards.
• The headline numbers are inputs, not outcomes: FDA device counts, hospital deployments, genomes sequenced. None of the three has published randomized, outcome-level evidence that its AI makes patients live longer.
• China's flagship "Agent Hospital" 93% score is a simulation (AI treating AI-generated patients); America's ~1,400 clearances mostly ran the 510(k) resemblance pathway; the UAE's genome bank has few published clinical endpoints so far.

Sources cited:

• FDA AI-Enabled Medical Devices
• CKGSB Knowledge
• Global Times
• Semafor
• medRxiv preprint
• G42 / M42
• SCMP / Deep Knowledge Group

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.